CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma. The company is also developing autologous CAR-T product candidates,